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TDP43 protein mislocalization is a hallmark of the neurodegenerative diseases amyotrophic lateral
sclerosis and frontotemporal dementia, and mutations in the gene encoding TDP43 cause both
disorders, further highlighting its role in disease pathogenesis. TDP43 is a heterogenous ribonucleo-
protein, therefore suggesting that alterations in RNA metabolism play a role in these disorders,
although direct evidence in patients is lacking. Sporadic inclusion body myositis (sIBM) is the most
common acquired myopathy occurring in adults aged older than 50 years and abnormal cytoplasmic
accumulations of TDP43 have been consistently described in sIBM myoﬁbers. Here, we exploit high
quality RNA from frozen sIBM muscle biopsies for transcriptomic studies on TDP43-proteinopathy
patient tissue. Surprisingly, we found widespread sIBM-speciﬁc changes in the RNA metabolism
pathways themselves. Consistent with this ﬁnding, we describe novel RNA binding proteins to mis-
localize in the cytoplasm of sIBM myoﬁbers and splicing changes in MAPT, a gene previously shown to
play a role in sIBM. Our data indicate widespread alterations of RNA metabolism are a novel aspect of
disease pathogenesis in sIBM. These ﬁndings also document an association, in TDP43-proteinopathy
patients, between heterogenous ribonucleoprotein pathology and RNA metabolism alterations and
carry importance for neurodegenerative diseases, such as amyotrophic lateral sclerosis and fronto-
temporal dementia.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
TDP43 is a 414-amino acid, prevalently nuclear, RNA binding
protein, encodedby the TARDBPgene,which is involved innumerouser the terms of the Creative
Works License, which per-
ion in any medium, provided
odegenerative Disease, UCL
. Tel.: þ44 (0)2034484448;
.
Published by Elsevier Inc. All righaspects of RNA metabolism including messenger RNA (mRNA)
splicing, stabilization, transport, and micro RNA biogenesis (Cohen
et al., 2011; Kawahara and Mieda-Sato, 2012). TDP43 is a major
component of the inclusions that characterize frontotemporal de-
mentia (FTD) andamyotrophic lateral sclerosis (ALS) central nervous
system pathology, and sporadic inclusion body myositis (sIBM)
muscle pathology (D’Agostino et al., 2011; Hernandez Lain et al.,
2011; Küsters et al., 2009; Mackenzie et al., 2010; Olivé et al.,
2009; Salajegheh et al., 2009; Weihl et al., 2008). As TARDBPmuta-
tions are also causative for both ALS and FTD, TDP43 may play a
primary unknown pathogenic role in these disorders, now referred
to as “TDP43proteinopathies” (Kabashi et al., 2008;Mackenzie et al.,
2010; Sreedharan et al., 2008). However, although impairment ints reserved.
A. Cortese et al. / Neurobiology of Aging 35 (2014) 1491e14981492RNA metabolism through TDP43 gain or loss of function has been
hypothesized (Lee et al., 2012; Polymenidou et al., 2011a; Tollervey
et al., 2011a), the poor quality of endstage brain postmortem mate-
rial means this yet remains to be demonstrated in patients.
sIBM is the most common muscle disease in adults aged older
than 50 years. sIBM muscle pathology is characterized by three
main components: (1) inﬂammatory changes; (2) degenerative
features; and (3) mitochondrial alterations (Amato and Barohn,
2009; Engel and Askanas, 2006; Needham and Mastaglia, 2007).
The pathogenesis of the disease is poorly understood and both
inﬂammatory and degenerative mechanisms may play a primary
role (Engel and Askanas, 2006; Needham and Mastaglia, 2007).
The numerous recent ﬁndings of cytoplasmic TDP43 inclusions
in sIBMmuscle ﬁbers (D’Agostino et al., 2011; Hernandez Lain et al.,
2011; Olivé et al., 2009; Salajegheh et al., 2009; Weihl et al., 2008),
have strengthened the link between sIBM and neurodegenerative
disorders, also supported by: (1) age of disease onset and its un-
responsiveness to immunosuppressive treatment; (2) identiﬁcation
of numerous neurodegeneration-characteristic proteins in the
ubiquitinated inclusions of sIBM muscle, such as abeta and tau
(Supplementary Table 2) (Askanas et al., 2009; Mirabella et al.,
1996); and (3) identiﬁcation of mutations in the VCP gene as a
cause of both ALS, and a complex phenotype which comprises an
hereditary form of inclusion body myopathy associated with FTD
(Johnson et al., 2010; Nalbandian et al., 2011).
Here, we exploit the excellent preservation of sIBM frozen
muscle biopsies to conduct pathology and transcriptomic analysis
on serial sections of patient TDP43-proteinopathy tissue. Surpris-
ingly, we ﬁndwidespread disruption in RNAmetabolism and for the
ﬁrst time, we believe, document such changes in patient TDP43-
proteinopathy tissue.
2. Methods
2.1. Patients
Muscle biopsies were obtained from 6 sIBM patients and 3
polymyositis (PM) patients. Muscle biopsies from 4 patients inves-
tigated for cramps or fatigue with normal examination and neuro-
physiology tests andnormal histologywere used as control subjects.
In sIBM and PM patients, biopsies were all taken from moderately
affected muscle and processed for routine histology and immuno-
histochemistry. If present, ﬁbrosis and fattymuscle inﬁltrationwere
never sowidespread tohamper a deﬁnitepathologic diagnosis. sIBM
patients fulﬁlled Griggs criteria for sIBM (Griggs et al., 1995). PM
patients reported subacute proximal muscle weakness, had raised
plasma creatine kinase levels, were steroid responsive and fulﬁlled
Bohan and Peter criteria (Bohan and Peter, 1975). Biopsies were
stored at 80 C. Details of patients and pathologic ﬁndings are
summarized in Supplementary Table 1. Institutional board reviewed
the study and ethical approval was obtained.
2.2. RNA extraction
Twenty-ﬁve slides 20-mm thick of muscle biopsies of normal and
patient muscle samples were homogenized in 1 mL of Trizol at 4 C.
RNA was isolated using RNeasy mini kit (Quiagen). RNA concentra-
tions were determined using Nanodrop spectrophotometer (ND-
1000). RNA was further analyzed for RNA quality on Agilent
Bioanalyzer, which showed RNA integrity number>6 for all samples.
2.3. Array hybridization
Up to 2 mg of total RNA was processed and labeled using the
Affymetrix GeneChip (Affymetrix, Santa Clara, CA, USA) wholetranscript sense target labeling assay as outlined in the manufac-
turer’s instructions. Hybridization to Affymetrix Human Exon 1.0 ST
arrays was performed for 16 hours at 45 C with constant rotation.
The arrays were scanned with an Affymetrix Gene Chip scanner
3000-system (Affymetrix). Initial data were processed to CEL ﬁles
using GeneChip operating software There are no versions to specify
for this sofware (Affymetrix).
2.4. Analysis of array gene expression data
Graphical plots of unsupervised hierarchical clustering were
generated using the Partek Genomic suite 6.6. All other statistical
analyses related to the expression data, including differential
expression analysis and principal component analysis (PCA) plots,
were generated using the R statistical software (v2.15.0), in
conjunction with the Bioconductor package limma (Smyth, 2004).
Microarray expression data were normalized using the robust
multi-array average procedure (Irizarry et al., 2003). For the dif-
ferential expression analysis, genes were ranked based on a t test
analysis and p-values were corrected for multiple testing using a
Benjamini-Hochberg False Discovery Rate (FDR) correction
(Benjamini and Hochberg, 1995).
Probe sets expression plots of genes of interest were subjected to
visual inspection to identify candidate alternatively spliced exons.
Lists of signiﬁcantly up- and down-regulated genes obtained from
statistical comparison were subjected to functional enrichment
analysis using DAVID (Database for Annotation, Visualization
and Integrated Discovery) (Huang et al., 2009). Exon array data are
available under accession number E-MTAB-2141 at the Array-
Express database (http://www.ebi.ac.uk/arrayexpress/).
2.5. Geneset enrichment analysis
GeneSet enrichment analysis was performed ranking datasets
by signal-to-noise ratio. Permutations were carried out by geneset
(n ¼ 1000) (Subramanian et al., 2005) http://www.broadinstitute.
org/gsea/index.jsp.
2.6. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA (150 ng) was reverse transcribed into ﬁrst-strand
complementary DNA (cDNA) using SuperScript VILO cDNA Synthe-
sis Kit (Invitrogen, Camarillo, CA, USA) and oligo(Dt). cDNA template
was ampliﬁed using FastStart PCR Master mix (Roche (Roche Di-
agnostics Ltd., Basel, Switzerland)) in a TC-Plus Thermocycler
(Techne, Burlington, NJ, USA). Primer sequences to amplify MAPT
exons 2, 6, and 10 and reference genes are as following: GAPDH-F
CCATGGCACCGTCAAGGCTGA; GAPDH-R GCCAGTAGAGGCAGGGAT
GAT; 18S-F AAACGGCTACCACATCCAAG; 18S-R CGCTCCCAAGATCC
AACTAC; MAPT-Ex9F AAGTCGCCGTCTTCCGCCAAG; MAPT-Ex11R
GTCCAGGGACCCAATCTTCGA; MAPT-Ex4-6F GAAGACGAAGCTGCTG
GTCA; MAPT-Ex4-6R TTGAGTTTCATCTCCTTTGC; MAPT-N-F CTTCTC
CTCCTCCGCTGTC;MAPT-0N-RCTGCTTCTTCAGCTTTCAGG;MAPT-1N-R
ATGCCTGCTTCTTCAGCTTC;MAPT-2N-RGAGCTCCCTCATCCACTAAGG.
PCR conditions were as follows: 5 minutes at 95 C, and then
28e34 cycles of 30 seconds at 94 C, 30 seconds at 59 C,1minute at
72 C with a ﬁnal 10 minute extension at 72 C. RT-PCR products
were detected on 2% agarose gel: 4R and 3R tau RT-PCR products
were 381 and 288 bp, respectively. The expected size for the PCR
product bearing MAPT exon 6 is 278 bp, whereas the products for
tau 0N, 1N, 2N, have an expected size of 212 bp, 303 bp, and 320 bp,
respectively. The expected sizes of the PCR products for GAPDH and
18S were respectively, 469 bp and 250 bp.
To calculate exon inclusion (I), the intensity of the peak rep-
resenting exon inclusion was divided by the intensity of peaks
Fig. 1. Immunohistochemistry analysis and transcriptomics performed on serial muscle sections. (A) Immunohistochemistry shows abnormal TDP43 cytoplasmic localization and
nuclear depletion (arrow) in sIBM myoﬁbers. (B) Quantiﬁcation of ﬁbers with TDP43 mislocalization normalized to biopsy surface area. (C) TARDBP expression measured with
Nanostring and (D) TARDBP 30UTR intron 7 alternative splicing show (In7DI indicates % changes in TARDBP intron 7 inclusion rate vs. control) no signiﬁcant changes amongst disease
groups. (E) Exon array hierarchical clustering. IBM sample 4 is the sample with the highest presence of TDP43 inclusions (B), the highest TARDBP levels (C) and lowest rate of TARDBP
intron 7 inclusion (D). Abbreviations: IBM, inclusion body myositis; PM, polymyositis; sIBM, sporadic inclusion body myositis.
A. Cortese et al. / Neurobiology of Aging 35 (2014) 1491e1498 1493representing both exon inclusion and exon skipping. Splicing
change (DI) was calculated by subtracting exon inclusion in the
sIBM or PM patients from the inclusion in control subjects
(Tollervey et al., 2011a). Statistical methods used to compare I and
DI of different exons across groups are outlined in Nanostring
methods paragraph.
2.7. Nanostring
Validation of microarray data was carried out on 23 genes
using NanoString nCounter (Seattle, WA, USA) on 11 of the 13
samples (5 sIBM, 3 PM, and 3 control subjects), excluding the 2
outliers IBM5 and Control3 as identiﬁed by microarrays. Probe
hybridization was carried out with 500-ng RNA for 18 hours in an
automated nCounter machine at NanoString. All genes on the
nCounter CodeSet were analyzed simultaneously in true multiplex
fashion. Three replicate runs were performed separately. Countswere collected as XLS ﬁles and then processed in 2 steps. Raw
counts were ﬁrst normalized using the mean of 6 internal spike-in
positive control probes for all samples to account for systematic
differences between assays. These control-normalized counts
were then further normalized to the expression level of 6 refer-
ence genes (ABCF1, ALAS1, LDHA, POLRI1B, RPLP0, SDHA) that we
selected as the most stable, with different expression levels, based
on microarray results. For data presentation, each gene count
value is shown as the mean of the replicates. To calculate exon
inclusion same methods as described in RT-PCR section were
applied. Statistical analysis of Nanostring and RT-PCR data were
performed using Graphpad Prism 5 software (GraphPad Software
Inc). Continuous variables were analyzed using either a 2-tailed t
test or a ManneWhitney U test as appropriate. If more than 2
groups were compared either analysis of variance or Kruskal-
Wallis test was used. The statistical signiﬁcance level was estab-
lished at p  0.05.
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To compare the mRNA expression data with the protein
expression of relevant genes, serial 7-mm frozen muscle sections
of the 13 samples were processed for immunostaining. The
following antibodies were used: TDP43 (Abnova, Taipei City,
Taiwan; 1:800); heterogenous ribonucleoprotein (hnRNP) A2/B1
(Abcam, UK; 1:100); hnRNP C1/C2 (Abcam, UK; 1:200); hnRNP H
(Abcam, UK; 1:200). Brieﬂy, frozen sections were postﬁxed in 4%
paraformaldehyde for 30-minutes at room temperature. Endog-
enous peroxidase activity was blocked with 0.3% H202 in meth-
anol and nonspeciﬁc binding with 10% dried milk solution.
Tissue sections were incubated with the primary antibodies
overnight at 4 C followed by biotinylated anti-mouse IgG
(1:200, 30 minutes; DAKO) (DAKO, Glostrup, Denmark) and
ABC complex (30 minutes; DAKO) (DAKO, Glostrup, Denmark).
Color was developed with di-aminobenzidine-H202. Finally,
counterstaining with hematoxylin was performed. The immu-
nostained sections were imaged with Olympus BX41 (Melville,
NY, USA).
3. Results and discussion
3.1. sIBM muscles show clear TDP43 pathology, but no changes in
TARDBP transcript level
To obtain transcriptomic data from pathologically well-
characterized tissue, we generated histology sections and RNA
from serial muscle biopsy sections of patients with sIBM
(n ¼ 6), PM (n ¼ 3), which presents inﬂammatory features
similar to sIBM (Rayavarapu et al., 2011), and normal control
subjects (n ¼ 4) (clinical detailseSupplementary Table 1). We
obtained expression data using Affymetrix Exon 1.0 ST arrays,
which target 270,366 human exons, and Nanostring nCounter
gene expression, which allows direct detection of RNA
molecules.
TDP43 immunohistochemistry (IHC) showed pathologic cyto-
plasmic staining in all but one sIBM patient (sIBM5) (Fig. 1). The
aggregates appeared as punctate cytoplasmic staining or larger
cytoplasmic inclusions. No TDP43 immunoreactivity was observed
outside nuclei in PM and normal control subjects.
TARDBP mRNA expression levels are tightly autoregulated by a
complex mechanism that acts through TDP43 binding its own
transcript and regulating an alternative splicing event in the
30UTR (Avendano-Vazquez et al., 2012), and have been reported
to be increased or unchanged in TDP43-proteinopathies
(Avendano-Vazquez et al., 2012; D’Agostino et al., 2011; Mishra
et al., 2007; Olivé et al., 2009; Salajegheh et al., 2009; Weihl
et al., 2008). We investigated upregulation and changes in the
autoregulation pattern by microarray and targeted Nanostring
analysis and found no evidence of differences in sIBM samples,
although one sample (sIBM4), that had by far the most severe
TDP43 pathology, had an increase in TARDBP mRNA and changes
in the autoregulation pattern compatible with an attempt to
compensate for high levels of TDP43 protein (Fig. 1). sIBM4 was
also characterized by having the longest interval between onset
and biopsy (Supplementary Table 1). These results suggest a
subset of samples may show upregulation, which may explain the
conﬂicting results in the literature, and future studies will be
useful to assess if this phenomenon is related to the stage of
disease.
Also, most of the transcripts which encoding proteins which
are relevant to sIBM pathology accumulations, as comprehensively
reviewed by Askanas et al., (2009), showed no signiﬁcant evidence
of increased mRNA levels (Supplementary Table 2).
Fig. 2. sIBM speciﬁc gene ontology (GO) analysis highlights dysregulation of RNA-related pathways. (A) Representation of sIBM versus control and PM versus control DEGs. (B) GO
analysis on sIBM speciﬁc DEGs highlights RNA related pathways and neurodegenerative diseases. (C) PCA1 and PCA2 analysis clusters samples by disease group; PCA1 separates
controls from both sIBM and PM, although PCA2 differentiates sIBM samples from both control and PM cases. (D) GO performed on genes contributing to the PCA2, conﬁrms the
dominant presence of RNA metabolism pathways. Abbreviations: DEGs, differentially expressed genes; PM, polymyositis; sIBM, sporadic inclusion body myositis.
A. Cortese et al. / Neurobiology of Aging 35 (2014) 1491e1498 14953.2. Identiﬁcation of sIBM speciﬁc transcripts points to widespread
alterations in RNA metabolism
Unsupervised hierarchical clustering of exon array data clearly
separated samples according to the disease group (Fig. 1E). PCA,
showed clustering of samples by disease group, but also identiﬁed 2
outliers: sIBM5, which was also atypical in lacking TDP43-
aggregates, and control sample 12, which were therefore removed
from further analysis (Supplementary Fig. 1). Exon arrays detected
expression of>22,000 transcripts, and statistical analysis identiﬁed
3323 and 3931 differentially expressed genes (DEG) that passed the
FDR-adjusted threshold (Benjamini-Hochberg FDR<0.05), between
control subjects and sIBMandPM, respectively. Arraydatavalidation
was carried out using the Nanostring platform to measure expres-
sion of 23 transcripts and by performing a comparison of DEGs using
publicly available microarray expression data on sIBM muscle
(Supplementary Tables 2a and 2b).
Gene ontology (GO) analysis for FDR-signiﬁcant genes using
DAVID (Database for Annotation, Visualization and Integrated Dis-
covery) (Huang et al., 2009), not surprisingly showed enrichment of
inﬂammatory-related terms, with GO terms being common to sIBM
and PM compared with control subjects (Table 1).
To identify sIBM speciﬁc DEGs, which are not a consequence of
the inﬂammatory process, we exploited the expression data from
PM samples, which have a very similar inﬂammatory inﬁltrate to
sIBM. We used 2 analytical approaches.
Firstly, using a 2-step procedure, we removed from the 3323
DEGs in sIBM versus control subjects, those also differentially
expressed in PM versus control subjects (FDR < 0.05). This analysis
identiﬁed 762 sIBM speciﬁc DEGs and 1244 PM speciﬁc DEGs
(Fig. 2A). GO analysis for sIBM revealed enrichment of ribonucleo-
protein complex and other ribonucleoprotein related terms(Fig. 2B). Signiﬁcant enrichment for RNA degradation, oxidative
phosphorylation, Parkinson disease, and Huntington disease KEGG
terms were also observed. Of note, mitochondrial dysfunction has
been hypothesized as a concurrent factor to the pathogenesis of
sIBM (Oldfors et al., 2006).
Our second analytical approach integrates the 3 disease groups
in a single step, exploiting the fact that, although PCA1 separates
control subjects from a joint IBM and/or PM group, PCA2 clearly
differentiates sIBM from both PM and controls (Fig. 2C). We ranked
genes according to their contribution to PCA2 (measured by the
magnitude of the PCA loadings) and selected genes for which the
magnitude of the gene-PCA loading was greater than 90% of the
maximum gene-PCA loading. GO analysis conﬁrmed enrichment of
terms related to RNA metabolism, including RNA splicing, RNA
binding, and mRNA metabolic process (Fig. 2D). Reassuringly, the
RNA metabolism GO terms found in both our sIBM speciﬁc lists,
were not enriched in the sublist of 1244 PM speciﬁc DEG
(Supplementary Table 4).
Of note, sIBM speciﬁc DEGs also included MATR3 and ZNF9,
known to cause 2 different “RNA-linked” myopathies, distal myop-
athy type 2 (Senderek et al., 2009), and myotonic dystrophy type 2
(Liquori et al., 2001), respectively.
3.3. Abnormal localization of other hnRNPs in sIBM
HNRNPA2/B1 and HNRNPH were signiﬁcantly downregulated in
sIBM (adjustedp¼0.004 andadjusted p¼0.003, respectively), other
hnRNPs includingHNRNPA1 and HNRNPCwere also downregulated,
but without statistical signiﬁcance after multiple-comparison
correction (p ¼ 0.08 and p ¼ 0.03). Since these genes belong to the
same family of ribonucleoproteins as TDP43, and have been shown
to interact with TDP43 and to be necessary for its splicing activity
Fig. 3. hnRNPA2/B1 and hnRNPC1/C2 mislocalize in sIBM myoﬁbers. Serial sections of sIBM muscle illustrate the occurrence of cytoplasmic “granular” staining of TDP43 (A),
hnRNPA2/B1 (B), and hnRNPC1/C2 (C, F) in different myoﬁbers. hnRNPA1 (D) and hnRNPH (E) do not showmislocalization. Arrows and arrowheads highlight the same ﬁber on serial
sections and illustrate how the abnormal cytoplasmic staining of these proteins can be independent. Abbreviations: hnRNP, heterogenous ribonucleoprotein; sIBM, sporadic
inclusion body myositis.
A. Cortese et al. / Neurobiology of Aging 35 (2014) 1491e14981496(Buratti et al., 2005; D’Ambrogio et al., 2009), we performed IHC
analysis of hnRNPA1, hnRNPA2/B1, hnRNPC1/C2, hnRNPH1, and
TDP43, on serial muscle sections. IHC for TDP43 revealed the pres-
ence of a cytoplasmic punctate granular staining in nonnecrotic
muscleﬁbers in 5 of 6 IBMpatients (Figs.1 and 3), but noneof the PM
and control subjects. A similar pattern of diffuse punctate cyto-
plasmic staining was also present for hnRNPA2/B1 and hnRNPC1/C2
in 4 of 6 and 5 of 6, IBM patients respectively. AMongst sIBM cases,
sIBM5wasnegative for TDP43, hnRNPA2/B1andhnRNPC1/C2. These
ﬁndingswere absent in biopsies of controlmuscle and polymyositis,
except for a positive cytoplasmic staining for hnRNPC2 in PM1.
Notably a recent study has identiﬁedmutations in HNRNPA1 and
HNRNPA2/B1 as causative for both ALS and hereditary inclusion
body myopathy and described abnormal localization of these pro-
teins, further adding support for the role of their proteins in sIBM
(Kim et al., 2013).
Interestingly, the same ﬁber often showed granular staining for
one of these proteins, but not the others (Fig. 2). This is in accor-
dance to the recent ﬁnding that hnRNPA1 and hnRNPA2/B1 are not
able to induce “cross-seeding” (Kim et al., 2013) and has important
pathogenetic implications, suggesting that these proteins do not
necessarily cooperate in these stages of disease, but their aggre-
gation may represent alternative, not exclusive, pathways in a
common disease process.
3.4. Long intron transcripts in sIBM muscle
Recent work from the Cleveland laboratory has documented an
effect of TDP43 loss of function on transcripts containing long in-
trons, and that this effect is common also to another ALS-related
hnRNP, FUS (Lagier-Tourenne et al., 2012; Polymenidou et al., 2011a).
We therefore investigated if an effect on such transcripts was present
in sIBM muscle, and indeed, Gene Set Enrichment Analysis showsthat transcripts with introns > 200 Kb are more signiﬁcantly down-
regulated in sIBM (normalized enrichment score 1.65, p < 0.0001),
although no signiﬁcant effect is seen in PM versus control subjects
(normalized enrichment score 0.67, p ¼ 0.9) (Supplementary Fig. 2)
(Subramanian et al., 2005). Enrichment and signiﬁcance are present
in the same direction and stronger when the same analysis is per-
formed, as a positive control, on the TDP43 knock-down material
used by Polymenidou et al (Polymenidou et al., 2011)
(Supplementary Fig. 2).3.5. MAPT splicing is altered in sIBM
The exon array data also identiﬁed exon speciﬁc differential
expression: using the extended Affymetrix probeset (807,542 probes),
and after applying a multiple testing Bonferroni correction (corrected
FDR <0.05), 157 exonic probes showed differential expression be-
tween IBM and control subjects, and 28 between PM and control
subjects.
The MAPT encoded tau protein has been shown to accumulate
and postulated to play a role in sIBM (Mirabella et al., 1996) and
MAPTalternative splicing plays a role in neurodegenerative diseases
(Niblock and Gallo, 2012). Thereforewe analyzedMAPT splicing and
our exon array data showed an increase in exon 6 inclusion in sIBM
(þ1.6 l log2-fold, FRD adjusted p< 0.05) (Fig. 4A). We then validated
these ﬁndings and also investigated the splicing of MAPT exons 2
and 10, known to play a role in neurodegenerative disorders, using
RT-PCR and Nanostring probes speciﬁc to “spliced-in” and “spliced-
out” isoforms. Overall these results indicate the presence of sIBM
speciﬁc changes in the splicing ofMAPT exon 6, although changes in
exons 2 and 10 are common also to PM samples and possibly reﬂect
inﬂammatory changes (Fig. 4BeH). Interestingly, exon 6 splicing
changes have been previously identiﬁed in postmortem brain of
Fig. 4. MAPT splicing analysis. (A) Exon arrays show an increasedMAPT exon 6 inclusion in sIBM (þ1.6 l log2-fold, FRD adjusted p < 0.05). (B) Agarose gel electrophoresis of RT-PCR
amplicons for MAPT exon 2, exon 6, and exon 10 alternative splicing events, and b-actin and GAPDH endogenous controls. (CeE) Quantiﬁcation of RT-PCRs of MAPT splicing events
normalized to both endogenous controls. (FeH) Nanostring analysis of MAPT splicing events. Differential exon inclusion indexes (DI) are represented relative to controls. Abbre-
viation: sIBM, sporadic inclusion body myositis.
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der in which RNA metabolism plays a clear role.
Conclusions
In conclusion our data reveal widespread changes in RNA
metabolism pathways occurring in sIBM TDP43-proteinopathy and
are supported by the ﬁnding that other novel hnRNPs mislocalize
and accumulate in the cytoplasm of sIBM TDP43-proteinopathy
(Kim et al., 2013). Importantly, and we believe for the ﬁrst time in
patient tissue, we link a TDP43-proteinopathy with generalized
hnRNP misregulation, both transcriptionally and at the level of
pathology. These results strongly support the view that RNA
metabolism alterations play a role in these disorders, and thatdownstream RNA misregulation is not the result of TDP43 pathol-
ogy alone, but is linked to the more complex misregulation of
numerous players.
Furthermore, our results highlight similarities between sIBM and
ALS and/or FTD and are consistent withmutations in VCP, and recently
in HNRNPA1 and HNRNPA2/B1, causing both ALS and IBMPFD (Kim
et al., 2013). The overlap between sIBM and neurodegenerative dis-
orders, such as ALS and FTD, offers a further tool, through techniques
such as single cell capture, for better dissecting and understanding the
pathogenesis of these diseases and identifying therapeutic targets.
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